Henan Lingrui Pharmaceutical (600285) Fundamentals 2026 — P/E 16.1x, Revenue Analysis | SniperIQ
Henan Lingrui Pharmaceutical (600285) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥12.7B, trading at ¥22.42 on the SHH. This SniperIQ fundamentals page covers Henan Lingrui Pharmaceutical's valuation (P/E 16.1x, P/B 3.5x), profitability (net margin 19.9%), revenue (¥3.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Henan Lingrui Pharmaceutical's market cap?
Henan Lingrui Pharmaceutical (600285) has a market capitalization of approximately ¥12.7B, trading at ¥22.42 on the SHH. Market cap moves with the live share price.
What is Henan Lingrui Pharmaceutical's P/E ratio?
Henan Lingrui Pharmaceutical's trailing twelve-month P/E ratio is 16.1x, with a price-to-book (P/B) of 3.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Henan Lingrui Pharmaceutical?
Henan Lingrui Pharmaceutical runs a net profit margin of 19.9%, a gross margin of 80.3%, and an operating margin of 22.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Henan Lingrui Pharmaceutical generate?
Henan Lingrui Pharmaceutical reported revenue of ¥3.9B for fiscal year 2025, with net income of ¥760M and earnings per share (EPS) of 1.34. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Henan Lingrui Pharmaceutical pay a dividend?
Henan Lingrui Pharmaceutical offers a trailing dividend yield of about 4.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Henan Lingrui Pharmaceutical financially healthy?
Henan Lingrui Pharmaceutical carries a debt-to-equity ratio of 0.08x and a current ratio of 1.17x, with a market beta of 0.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Henan Lingrui Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Henan Lingrui Pharmaceutical (600285) the key facts are: market cap ¥12.7B, P/E 16.1x, revenue ¥3.9B, 52-week range 19-24.75. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Henan Lingrui Pharmaceutical's full fundamentals live
Get Henan Lingrui Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.